Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryEvery month, Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA’s own review documents, including the discipline reviews, decision memos, meeting minutes, emails, and other documents, we strive to illuminate the agency decision-making process.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.